Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is a dominant player in the pharmaceutical industry with a strong portfolio of products and a diverse pipeline focused on addressing major healthcare needs. The company's strong sales forecast and forecasted EPS growth suggest a strong future performance. Additionally, the company's commitment to sustainability and focus on diversity and inclusion in clinical trials show long-term potential for consistent growth and market leadership. Potential downside risks include pricing pressure and competition in the GLP-1 market, as well as potential negative pipeline trial results. As a result, an Outperform rating is appropriate with a 12-month price target of $1,500, based on a 30x multiple on forward fully diluted operating EPS forecast.

Bears say

Eli Lilly is a well-established pharmaceutical company with a diverse portfolio including products in neuroscience, cardiometabolic, cancer, and immunology. However, due to concerns surrounding slowing growth and potential pricing pressures in key products like Mounjaro and Trulicity, as well as uncertainties around the success of pipeline products such as Foundayo and retatrutide, our negative outlook for the stock is based on the potential for underperformance in the market. Furthermore, while the company has several promising potential catalysts in the horizon which could drive growth, the perceived high valuation and potential market-cap risks may overshadow these potential positive developments.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,307.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,307.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.